Endovision

Market position

Endovision positions Cerebro as one of the first Computer-Aided Quantification (CAQ) tools for esophagogastroduodenoscopy, focusing on upper GI examination quality and completeness rather than colonoscopy polyp detection. Its planned availability with Medtronic's GI Genius system via Cosmo Pharmaceuticals places it within the established intelligent-endoscopy ecosystem. External clinicians quoted on the company site, including the ESGE President-Elect, characterize the system as a proof of concept for ensuring complete gastric mucosa inspection while noting that additional clinical studies are desirable.

Rather than focusing solely on lesion detection, Cerebro emphasizes examination quality: real-time anatomical landmark navigation, image quality assessment, coverage scoring and automated photo-documentation across up to nine anatomical stations, delivered as a stand-alone software layer compatible with multiple imaging modalities (WLI, NBI, TXI) and designed not to disrupt existing procedure workflow.

Technology

Cerebro applies machine learning and computer vision to live endoscopic video. It performs real-time detection of key anatomical landmarks, assesses image quality and inspection completeness, tracks scope progression to reduce blind spots, and automatically detects up to nine anatomical stations during EGD to support structured photo-documentation. It generates structured end-of-procedure reports including landmark screenshots and an inspection coverage score, and works across WLI, NBI and TXI imaging modalities. The company describes the product as a stand-alone SaMD designed to integrate into existing clinical setups and built to medical device regulatory requirements.

Go-to-market

The company markets directly to healthcare professionals through its website and clinical advisory relationships with senior endoscopists in Hong Kong, Japan and Europe, and has announced a partnership with Cosmo Pharmaceuticals to make its AI available with Medtronic's GI Genius intelligent endoscopy system. CE certification of Cerebro supports commercialization in Europe.

Endoscopists, gastroenterologists and upper-GI surgeons performing EGD, and the hospitals and endoscopy units in which they work.

Geography

Two offices are listed: Hong Kong (Building 1E, Phase One, Hong Kong Science Park, Pak Shek Kok, New Territories) and New Delhi, India (Dwarka, South West Delhi). Entrepreneur First lists the company under its Hong Kong cohort context; clinical partners are based in Hong Kong, Japan, Norway and Italy, and CE certification supports European market access.

History

Endovision appears in the Entrepreneur First portfolio and lists Entrepreneur First and MedTech Innovator as accelerators, alongside Pureland Venture, Hong Kong Science Park (government funding and incubation) and the CUHK Faculty of Medicine as a collaborating research institution. Its product Cerebro subsequently obtained CE certification, and the company announced a partnership with Cosmo Pharmaceuticals for distribution alongside Medtronic's GI Genius system. Precise dates for these milestones are not stated in the sources.

Risks & controversies

Clinical validation appears early-stage: ESGE President-Elect Cesare Hassan describes Cerebro as a proof of concept and states that additional clinical studies are desirable. Publicly available information is limited almost entirely to the company's own website, with no disclosed funding amounts, revenue, headcount or independent deployment data. Note that several similarly named entities exist (Endovision Foundation, a US 501(c)(3) charity, and KARL STORZ Endovision, Inc.) and are unrelated to this company.